Literature DB >> 17085852

Prodrugs and soft drugs.

Andrzej Stańczak1, Anna Ferra.   

Abstract

This review focuses on a new approach to the development of drugs, namely on prodrugs and soft drugs. Nowadays, we try to design drugs that heal sick people having the best acceptance of patients. They must be efficient and selective on their site of action and must be metabolized to non-toxic derivatives. Both, prodrugs and soft drugs should have good distributive properties to enhance their quality. They are designed to maximize the amount of an active drug that reaches its target, through changing the physicochemical, biopharmaceutical or pharmacokinetic properties of drugs. Prodrugs are changed into the active drug within the body through enzymatic or non-enzymatic reactions. Soft drugs are novel and active analogues of already known therapeutic agents. It is expected that continued studies will improve drug properties so as to achieve the best drug delivery system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17085852

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  9 in total

1.  Lisdexamfetamine dimesylate: the first prodrug stimulant.

Authors:  David W Goodman
Journal:  Psychiatry (Edgmont)       Date:  2007-08

2.  Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.

Authors:  Richard H Weisler; Ann C Childress
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Unraveling the Metabolic Routes of Retapamulin: Insights into Drug Development of Pleuromutilins.

Authors:  Feifei Sun; Huiyan Zhang; Gerard Bryan Gonzales; Jinhui Zhou; Yi Li; Jinzhen Zhang; Yue Jin; Zhanhui Wang; Yanshen Li; Xingyuan Cao; Suxia Zhang; Shupeng Yang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 4.  Structural Modification in Anesthetic Drug Development for Prodrugs and Soft Drugs.

Authors:  Chaoyi Deng; Jin Liu; Wensheng Zhang
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

5.  Distinct Hypnotic Recoveries After Infusions of Methoxycarbonyl Etomidate and Cyclopropyl Methoxycarbonyl Metomidate: The Role of the Metabolite.

Authors:  Ervin Pejo; Jifeng Liu; Xiangjie Lin; Douglas E Raines
Journal:  Anesth Analg       Date:  2016-04       Impact factor: 5.108

6.  A new antiviral: chimeric 3TC-AZT phosphonate efficiently inhibits HIV-1 in human tissues ex vivo.

Authors:  Christophe Vanpouille; Anastasia Khandazhinskaya; Inna Karpenko; Sonia Zicari; Victor Barreto-de-Souza; Svetlana Frolova; Leonid Margolis; Sergey Kochetkov
Journal:  Antiviral Res       Date:  2014-07-07       Impact factor: 5.970

7.  Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics.

Authors:  Yingchao Li; Yongjun Wang; Ran Zhang; Cuiru Liu; Yue Wei; Jin Sun; Zhonggui He; Youjun Xu; Tianhong Zhang
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

8.  AZT 5'-Phosphonates: Achievements and Trends in the Treatment and Prevention of HIV Infection.

Authors:  Capital A Cyrillic L Khandazhinskaya; E A Shirokova
Journal:  Acta Naturae       Date:  2013-07       Impact factor: 1.845

9.  Crystal structure of ammonium 3'-azido-3'-de-oxy-thymidine-5'-amino-carbonyl-phospho-nate hemi-hydrate: an anti-HIV agent.

Authors:  Maxim V Jasko; Galina V Gurskaya; Marina K Kukhanova; Ivan S Bushmarinov
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.